[Prostaglandin analogues and central corneal thickness]

Area of Science:

• Ophthalmology
• Corneal Physiology
• Glaucoma Management

Background:

• Prostaglandin analogs lower intraocular pressure (IOP) by activating matrixmetalloproteinase enzymes (MMP).
• MMP activation in the cornea can alter central corneal thickness (CCT).
• Understanding CCT changes is crucial for glaucoma treatment efficacy.

Purpose of the Study:

• To compare the effects of different prostaglandin analogs on central corneal thickness (CCT).
• To evaluate CCT changes in patients treated with travoprost versus latanoprost.
• To assess the impact of prostaglandin analog therapy on corneal parameters.

Main Methods:

• A 3-month prospective, randomized clinical study involving 26 patients with newly diagnosed primary open-angle glaucoma or ocular hypertension.
• Patients were assigned to topical treatment with either travoprost 0.004% (Group I, n=15) or latanoprost 0.005% (Group II, n=11), administered nightly.
• Central corneal thickness (CCT) was measured using ultrasound pachymetry at baseline, 1 month, and 3 months. Statistical analysis employed the Mann-Whitney test.

Main Results:

• Mean baseline CCT was similar between groups (521.27±28.54 µm for travoprost, 522.18±27.52 µm for latanoprost).
• Both travoprost and latanoprost groups showed a statistically significant reduction in CCT over 3 months.
• The CCT reduction was comparable between the two groups at 1 and 3 months.

Conclusions:

• Both travoprost and latanoprost, as prostaglandin analogs, effectively reduce mean central corneal thickness (CCT).
• The observed effect on CCT reduction is equivalent between the travoprost and latanoprost treatment groups.
• These findings suggest similar corneal impacts of commonly prescribed prostaglandin analogs in glaucoma management.